Steroidal scaffolds as FXR and GPBAR1 ligands: From chemistry to therapeutical application

Future Medicinal Chemistry

Volumn 7, Issue 9, 2015, Pages 1109-1135

  Sepe, Valentina ^a   Distrutti, Eleonora ^b   Limongelli, Vittorio ^a,c   Fiorucci, Stefano ^d   Zampella, Angela ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^c UNIVERSITY OF LUGANO   (Switzerland)

^d UNIVERSITY OF PERUGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL DERIVATIVE; BILE ACID; CHOLESTEROL; FARNESOID X RECEPTOR; G PROTEIN COUPLED BILE ACID RECEPTOR 1; G PROTEIN COUPLED RECEPTOR; MOLECULAR SCAFFOLD; NEUROSTEROID; STEROID HORMONE; TRITERPENOID; UNCLASSIFIED DRUG; BIOLOGICAL PRODUCT; CELL RECEPTOR; FARNESOID X-ACTIVATED RECEPTOR; GPBAR1 PROTEIN, HUMAN; LIGAND; STEROID; TERPENE;

BILE ACID SYNTHESIS; CELL NUCLEUS; ENTEROHEPATIC CIRCULATION; HUMAN; MEDICINAL CHEMISTRY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SENSOR; SIGNAL TRANSDUCTION; AGONISTS; BINDING SITE; CHEMISTRY; METABOLISM; MOLECULAR DOCKING;

BILE ACIDS AND SALTS; BINDING SITES; BIOLOGICAL PRODUCTS; HUMANS; LIGANDS; MOLECULAR DOCKING SIMULATION; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, G-PROTEIN-COUPLED; STEROIDS; TERPENES;

EID: 84935104054     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.15.54     Document Type: Review

References (117)

1. Makishima M, Okamoto AY, Repa JJ et al. Identifcation of a nuclear receptor for bile acids. Science 284, 1362-1365 (1999).
2. Parks DJ, Blanchard SG, Bledsoe RK et al. Bile acids: natural ligands for an orphan nuclear receptor. Science 284, 1365-1368 (1999).
3. Wang H, Chen J, Hollister K et al. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol. Cell 3, 543-553 (1999).
4. Xie W, Radominska-Pandya A, Shi Y et al. An essential role for nuclear receptors SXR/PXR in detoxifcation of cholestatic bile acids. Proc. Natl Acad. Sci. USA 98, 3375-3380 (2001).
5. Makishima M, Lu TT, Xie W et al. Vitamin D receptor as an intestinal bile acid sensor. Science 296, 1313-1316 (2002).
6. Maruyama T, Miyamoto Y, Nakamura T et al. Identifcation of membrane type receptor for bile acids (M-BAR). Biochem. Biophys. Res. Commun. 298, 714-719 (2002).
7. Sheikh Abdul Kadir SH, Miragoli M, Abu-Hayyeh S et al Bile acid-induced arrhythmia is mediated by muscarinic M2 receptors in neonatal rat cardiomyocytes. PLoS ONE 5, e9689 (2010).
8. Fiorucci S, Zampella A, Distrutti E. Development of FXR, PXR and CAR agonists and antagonists for treatment of liver disorders. Curr. Top. Med. Chem. 12, 605-624 (2012).
9. Fiorucci S, Cipriani S, Baldelli F et al. Bile acid-activated receptors in the treatment of dyslipidemia and related disorders. Prog. Lipid Res. 49, 171-185 (2010).
10. Fiorucci S, Mencarelli A, Palladino G et al. Bile-acid-activated receptors: targeting TGR5 and farne so id-X-receptor in lipid and glucose disorders. Trends Pharmacol. Sci. 30, 570-580 (2009).
11. Fiorucci S, Rizzo G, Donini A et al. Targeting farnesoid X receptor for liver and metabolic disorders. Trends Mol. Med. 13, 298-309 (2007).
12. Swanson HI, Wada T, Xie W et al. Role of nuclear receptors in lipid dysfunction and o be sity-related diseases. Drug Metab. Dispos. 41, 1-11 (2013).
13. Fiorucci S, Mencarelli A, Distrutti E et al. Farnesoid X receptor: from medicinal chemistry to clinical applications. Future Med. Chem. 4, 877-891 (2012).
14. Modica S, Petruzzelli M, Bellafante E et al. Selective activation of nuclear bile acid receptor FXR in the intestine protects mice against cholestasis. Gastroenterology 142, 355-365 (2012).
15. Degirolamo C, Rainaldi S, Bovenga F et al. Microbiota modifcation with probiotics induces hepatic bile acid synthesis via down regulation of the Fxr-Fgf15 axis in mice. Cell Rep. 7, 12-18 (2014).
16. Mencarelli A, Renga B, D'Amore C et al. Dissociation of intestinal and hepatic activities of FXR and LXRα supports metabolic effects of terminal ileum interposition in rodents. Diabetes 62, 3384-3393 (2013).
17. Fang S, Suh JM, Reilly SM et al. Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance. Nat. Med. 21, 159-165 (2015).
18. Jiang C, Xie C, Li F et al. Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease. J. Clin. Invest. 125, 386-402 (2015).
19. Vavassori P, Mencarelli A, Renga B et al. The bile acid receptor FXR is a modulator of intestinal innate immunity. J. Immunol. 183, 6251-6261 (2009).
20. Wang L, Lee YK, Bundman D et al. Redundant pathways for negative feedback regulation of bile acid production. Dev. Cell 2, 721-731 (2002).
21. Eloranta JJ, Meier PJ, Kullak-Ublick GA. Coordinate transcriptional regulation of transport and metabolism. Methods Enzymol. 400, 511-530 (2005).
22. Kullak-Ublick GA, Stieger B, Meier PJ. Enterohepatic bile salt transporters in normal physiology and liver disease. Gastroenterology 126, 322-342 (2004).
23. Inagaki T, Choi M, Moschetta A et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab. 2, 217-225 (2005).
24. Owen BM, Mangelsdorf DJ, Kliewer SA. Tissue-specifc actions of the metabolic hormones FGF15/19 and FGF21. Trends Endocrinol. Metab. 26, 22-29 (2015).
25. Fiorucci S, Distrutti E, Ricci P et al. Targeting FXR in cholestasis: hype or hope. Expert Opin. Ther. Targets 12, 1449-1459 (2014).
26. Davern TJ, Scharschmidt BF. Biochemical liver test. In: Gastrointestinal and Liver Disease, Sleisenger and Fordtran's Edition. Elsevier, USA, 1227-1237 (2002).
27. Momah N, Lindor KD. Primary biliary cirrhosis in adults. Expert Rev. Gastroenterol. Hepatol. 4, 427-433 (2014).
28. Mayo MJ. Cholestatic liver disease overlap syndromes. Clin. Liver Dis. 2, 243-253 (2013).
29. Hirschfeld GM, Karlsen TH, Lindor KD et al. Primary sclerosing cholangitis. Lancet 382, 1587-1599 (2013).
30. Ahmed KT, Almashhrawi AA, Rahman RN et al. Liver diseases in pregnancy: diseases unique to pregnancy. World J. Gastroenterol. 43, 7639-7646 (2013).
31. Van der Woerd WL, van Mil SW, Stapelbroek JM et al. Familial cholestasis: progressive familial intrahepatic cholestasis, benign recurrent intrahepatic cholestasis and intrahepatic cholestasis of pregnancy. Best Pract. Res. Clin. Gastroenterol. 5, 541-553 (2010).
32. Lieu T, Jayaweera G, Bunnett N W. GPBA: a GPCR for bile acids and an emerging therapeutic target for disorders of digestion and sensation. Br. J. Pharmacol. 171, 1156-1166 (2014).
33. Poole DP, Godfrey C, Cattaruzza F et al. Expression and function of the bile acid receptor GP-BAR1 (TGR5) in the murine enteric nervous system. Neurogastroenterol. Motil. 22, 814-825 (2010).
34. Alemi F, Poole DP, Chiu J et al. The receptor TGR5 mediates the prokinetic actions of intestinal bile acids and is required for normal defecation in mice. Gastroenterology 144, 145-154 (2013).
35. Bunnett NW. Neuro-humoral signalling by bile acids and the TGR5 receptor in the gastrointestinal tract. J. Physiol. 592, 2943-2950 (2014).
36. Camilleri M, Vazquez-Roque MI, Carlson P et al. Association of bile acid receptor TGR5 variation and transit in health and lower functional gastrointestinal disorders. Neur o gastro ent er ol. Motil. 11, 95-99 (2011).
37. Katsuma S, Hirasawa A, Tsujimoto G. Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1. Biochem. Biophys. Res. Commun. 1, 386-390 (2005).
38. Thomas C, Gioiello A, Noriega L et al. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab. 3, 167-177 (2009).
39. Fiorucci S, Cipriani S, Mencarelli A et al. Counter-regulatory role of bile acid activated receptors in immunity and infammation. Curr. Mol. Med. 6, 79-95 (2010).
40. Cipriani S, Mencarelli A, Chini MG et al. The bile acid receptor GPBAR-1 (TGR5) modulates integrity of intestinal barrier and immune response to experimental colitis. PLoS ONE 6, e25637 (2011).
41. Hov JR, Keitel V, Laerdahl JK et al. Mutational characterization of the bile acid receptor TGR5 in primary sclerosing cholangitis. PLoS ONE 8, e12403 (2010).
42. Lieu T, Jayaweera G, Zhao P et al. The bile acid receptor TGR5 activates the TRPA1 channel to induce itch in mice. Gastroenterology 147, 1417-1428 (2014).
43. Singh RB, Niaz MA, Ghosh S. Hypolipidemic and antioxidant effects of Commiphora mukul as an adjunct to dietary therapy in patients with hypercholesterolemia. Cardiovasc. Drugs Ther. 4, 659-664 (1994).
44. Sinal CJ, Gonzalez FJ. Guggulsterone: an old approach to a new problem. Trends Endo crin. Met. 13, 275-276 (2002).
45. Urizar NL, Liverman AB, Dodds DT et al. A natural product that lowers cholesterol as an antagonist ligand for FXR. Science 296, 1703-1706 (2002).
46. Wu J, Xia C, Meier J et al. The hypolipidemic natural product guggulsterone acts as an antagonist of the bile acid receptor. Mol. Endocrinol. 16, 1590-1597 (2002).
47. Cui J, Huang L, Zhao A et al. Guggulsterone is a farnesoid X receptor antagonist in coactivator association assays but acts to enhance transcription of bile salt export pump. J. Biol. Chem. 278, 10214-10220 (2003).
48. Szapary PO, Wolfe ML, Bloedon LT et al. Guggulipid for the treatment of hypercholesterolemia: a randomized controlled trial. J. Am. Med. Assoc. 290, 765-772 (2003).
49. Burris TP, Montrose C, Houck KA et al. The hypolipidemic natural product guggulsterone is a promiscuous steroid receptor ligand. Mol. Pharmacol. 67, 948-954 (2005).
50. D Auria MV, Sepe V, Zampella A. Natural ligands for nuclear receptors: biology and potential therapeutic applications. Curr. Top. Med. Chem. 12, 637-669 (2012).
51. Meng Q, Chen X, Wang C et al. Alisol B 23-acetate promotes liver regeneration in mice after partial hepatectomy via activating farnesoid X receptor. Biochem. Pharmacol. 92, 289-298 (2014).
52. Mi LZ, Devarakonda S, Harp JM et al. Structural basis for bile acid binding and activation of the nuclear receptor FXR. Mol. Cell. 11, 1093-1100 (2003).
53. Grienke U, Mihály-Bison J, Schuster D et al. Pharmacophore-based discovery of FXR-agonists. Part II: identifcation of bioactive triterpenes from Ganoderma lucidum. Bioorg. Med. Chem. 19, 6779-6791 (2011).
54. Zou J, Jiang J, Diao Y-Y et al. Cycloartane triterpenoids from the stems of Schisandra glaucescens and their bioactivity. Fitoterapia 83, 926-931 (2012).
55. Carter BA, Taylor OA, Prendergast DR et al. Stigmasterol, a Soy lipid-derived phytosterol, is an antagonist of the bile acid nuclear receptor FXR. Pediatr. Res. 62, 301-306 (2007).
56. Fiorucci S, Distrutti E, Bifulco G et al. Marine sponge steroids as nuclear receptor ligands. Trends Pharmacol. Sci. 33, 591-601 (2012).
57. Shin K, Chin J, Hahn D et al. Sterols from a soft coral, Dendronephthya gigantean as farnesoid X-activated receptor antagonists. Steroids 77, 355-359 (2012).
58. Nam S-J, Ko H, Shin M et al. Farnesoid X-activated receptor antagonists from a marine sponge Spongia sp. Bioorg. Med. Chem. Lett. 16, 5398-5402 (2006).
59. Nam S-J, Ko HL, Ju MK et al. Scalarane sesterterpenes from a marine sponge of the genus Spongia and their FXR antagonistic activity. J. Nat. Prod. 70, 1691-1695 (2007).
60. Sepe V, Bifulco G, Renga B et al. Discovery of sulfated sterols from marine invertebrates as a new class of marine natural antagonists of farnesoid-X-receptor. J. Med. Chem. 54, 1314-1320 (2011).
61. De Marino S, Ummarino R, DAuria MV et al. Theonellasterols and conicasterols from Theonella swinhoei. Novel marine natural ligands for human nuclear receptors. J. Med. Chem. 54, 3065-3075 (2011).
62. De Marino S, Ummarino R, DAuria MV et al. 4-Methylenesterols from Theonella swinhoei sponge are natural pregnane-X-receptor agonists and farnesoid-X-receptor antagonists that modulate innate immunity. Steroids 77, 484-495 (2012).
63. Sepe V, Ummarino R, D Auria MV et al. Conicasterol E, a small heterodimer partner sparing farnesoid X receptor modulator endowed with a pregnane X receptor agonistic activity, from the marine sponge Theonella swinhoei. J. Med. Chem. 55, 84-93 (2012).
64. Chini MG, Jones CR, Zampella A et al. Quantitative NMR-derived interproton distances combined with quantum mechanical calculations of 13C chemical shifts in the stereochemical determination of conicasterol F, a nuclear receptor ligand from Theonella swinhoei. J. Org. Chem. 77, 1489-1496 (2012).
65. Renga B, Mencarelli A, DAmore C et al. Discovery that theonellasterol a marine sponge sterol is a highly selective FXR antagonist that protects against liver injury in cholestasis. PLoS ONE 7, e30443 (2012).
66. Sepe V, Ummarino R, D Auria MV et al. Preliminary structure-activity relationship on theonellasterol, a new chemotype of FXR antagonist, from the marine sponge Theonella swinhoei. Marine Drugs 10, 2448-2466 (2012).
67. Di Leva FS, Festa C, DAmore C et al. Binding mechanism of the farnesoid X receptor marine antagonist suvanine reveals a strategy to forestall drug modulation on nuclear receptors. Design, synthesis, and biological evaluation of novel ligands. J. Med. Chem. 56, 4701-4717 (2013).
68. Pellicciari R, Fiorucci S, Camaioni E et al. 6R-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J. Med. Chem. 45, 3569-3572 (2002).
69. Yeh GY, Kaptchuk TK, Eisenberg DM et a l. Systematic review of herbs and dietary supplements for glycemic control in diabetes. Diabetes Care 26, 1277-1294 (2003).
70. Yeh GY, Eisenberg DM, Davis RB et al. Complementary and alternative medicine use among patients with diabetes mellitus: result of a national survey. Am. J. Pub. Health 92, 1648-1652 (2002).
71. Sato H, Genet C, Strehle A et al. Anti-hyperglycemic activity of a TGR5 agonist isolated from O lea europaea. Biochem. Biophys. Res. Commun. 362, 793-798 (2007).
72. Liby KT, Yore MM, Sporn MB. Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer. Nat. Rev. Cancer 7, 357-369 (2007).
73. Kumar DP, Rajagopal S, Mahavadi S et al. Activation of transmembrane bile acid receptor TGR5 stimulates insulin secretion in pancreatic ß cells. Biochem. Biophys. Res. Commun. 427, 600-605 (2012).
74. Genet C, Strehle A, Schmidt C et al. Structure-activity relationship study of betulinic acid, a novel and selective TGR5 agonist, and its synthetic derivatives: potential impact in diabetes. J. Med. Chem. 53, 178-190 (2010).
75. Ono E, Inoue J, Hashidume T et al. Anti-obesity and anti-hyperglycemic effects of the dietary citrus limonoid nomilin in mice fed a high-fat diet. Biochem. Biophys. Res. Comm. 410, 677-681 (2011).
76. Roy A, Saraf S. Limonoids: overview of signifcant bioactive triterpenes distributed in plants kingdom. Biol. Pharm. Bull. 29, 191-201 (2006).
77. Manners GD. Citrus limonoids: analysis, bioactivity, and biomedical prospects. J. Agric. Food Chem. 55, 8285-8294 (2007).
78. Macchiarulo A, Gioiello A, Rosatelli E et al. Patented TGR5 modulators: a review (2006-present). Expert Opin. Ther. Pat. 12, 1399-1414 (2012).
79. Mudaliar S, Henry RR, Sanyal AJ et al. Effcacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology 145, 574-582 (2013).
80. Fiorucci S, Clerici C, Antonelli E et al. Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis. J. Pharmacol. Exp. Ther. 313, 604-612 (2005).
81. Fiorucci S, Cipriani S, Mencarelli A et al. Farnesoid X receptor agonist for the treatment of liver and metabolic disorders: focus on 6-ethyl-CDCA. Mini-Rev. Med. Chem. 11, 753-762 (2011).
82. Hirschfeld GM, Mason A, Luketic V et al. Effcacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterology 148 751-761 (2015).
83. Neuschwander-Tetri BA, Loomba R, Sanyal AJ et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 385, 956-965 (2015).
84. Rizzo G, Passeri D, De Franco F et al. Functional characterization of the semisynthetic bile acid derivative INT-767, a dual farnesoid X receptor and TGR5 agonist. Mol. Pharmacol. 78, 617-630 (2010).
85. Pellicciari R, Sato H, Gioiello A et al. Non genomic actions of bile acids. Synthesis and preliminary characterization of 23-and 6, 23-alkyl-substituted bile acid derivatives as selective modulators for the G-protein coupled receptor TGR5. J. Med. Chem. 50, 4265-4268 (2007).
86. Dopico AM, Walsh JV Jr, Singer JJ. Natural bile acids and synthetic analogues modulate large conductance Ca2+-activated K+ (BKCa) channel activity in smooth muscle cells. J. Gen. Physiol. 3, 51-73 (2002).
87. Mencarelli A, Renga B, Distrutti E et al. Antiatherosclerotic effect of farnesoid X receptor. Am. J. Physiol. Heart Circ. Physiol. 296, H272-H281 (2009).
88. Pellicciari R, Gioiello A, Sabbatini P et al. Avicholic acid: a lead compound from birds on the route to potent TGR5 modulators. A CS Med. Chem. Lett. 3, 273-277 (2012).
89. DAmore C, Di Leva FS, Sepe V et al. Design, synthesis, and biological evaluation of potent dual agonists of nuclear and membrane bile acid receptors. J. Med. Chem. 57, 937-954 (2014).
90. Cipriani S, Mencarelli A, Palladino G et al. FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats. J. Lipid. Res. 51, 771-784 (2010).
91. Baghdasaryan A, Claudel T, Gumhold J et al. Dual farnesoid X receptor/TGR5 agonist INT-767 reduces liver injury in the Mdr2-/-(Abcb4-/-) mouse cholangiopathy model by promoting biliary HCO-output. Hepatology 54, 1303-1312 (2011).
92. Pellicciari R, Fiorucci S, Pruzanski M. Preparation of bile acid derivatives as FXR ligands for the prevention or treatment of FXR-mediated diseases or conditions. P CT Int. WO 2008002573 A2 20080103 (2008).
93. Festa C, Renga B, DAmore C et al. Exploitation of cholane scaffold for the discovery of potent and selective farnesoid X receptor (FXR) and G-protein coupled bile acid receptor 1 (GPBAR1) ligands. J. Med. Chem. 57, 8477-8495 (2014).
94. Pellicciari R, Gioiello A, Costantino G et al. Back door modulation of the farnesoid X receptor: design, synthesis, and biological evaluation of a series of side chain modifed chenodeoxycholic acid derivatives. J. Med. Chem. 49, 4208-4215 (2006).
95. Macchiarulo A, Gioiello A, Thomas C et al. Probing the binding site of bile acids in TGR5. ACS Med. Chem. Lett. 4, 1158-1162 (2013).
96. Gioiello A, Macchiarulo A, Carotti A et al. Extending SAR of bile acids as FXR ligands: discovery of 23-N-(carbocinnamyloxy)-3ct, 7ct-dihydroxy-6a-ethyl-24-nor-5ß-cholan-23-amine. Bioorg Med. Chem. 19, 2650-2658 (2011).
97. Pellicciari R, Gioiello A, Macchiarulo A et al. Discovery of 6R-ethyl-23(S)-methylcholic acid (S-EMCA, INT-777) as a potent and selective agonist for the TGR5 receptor, a novel target for diabesity. J. Med. Chem. 52, 7958-7961 (2009).
98. Thomas C, Gioiello A, Noriega L et al. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab. 10, 167-177 (2009).
99. Pols TWH, Nomura M, Harach T et al. TGR5 activation inhibits atherosclerosis by reducing macrophage infammation and lipid loading. Cell Metab. 14, 747-757 (2011).
100. Suzuki T, Tamehiro N, Sato Y et al. The novel compounds that activate farnesoid X receptor: the diversity of their effects on gene expression. J. Pharmacol. Sci. 107, 285-294 (2008).
101. Sato H, Macchiarulo A, Thomas C et al. Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies. J. Med. Chem. 51, 1831-1841 (2008).
102. Fukuchi J, Song C, Dai Q et al. 5ß-Cholane activators of the farnesol X receptor. J. Steroid Biochem. Mol. Biol. 94, 311-318 (2005).
103. Kim I, Morimura K, Shah Y et al. Spontaneuos hepatocarcinogenesis in farnesoid X receptor-null mice. Carcinogenesis 28, 940-946 (2007).
104. Yang F, Huang XF, Yi TS et al. Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor. Cancer Res. 67, 863-867 (2007).
105. Meng ZP, Wang XO, Gan YC et al. Deletion of IFNy enhances hepatocarcinogenesis in FXR knockout mice. J. Hepatol. 57, 1004-1012 (2012).
106. Jia L, Jiang D, Hu P et al. Synthesis and evaluation of 18F-labeled bile acid compound: a potential PET imaging agent for FXR-related diseases. Nuclear Med. Biol. 41, 495-500 (2014).
107. Schaap FG, Trauner M, Jansen PL. Bile acid receptors as targets for drug development. Nat. Rev. Gastroenterol. Hepatol. 1, 55-67 (2014).
108. Iguchi Y, Nishimaki-Mogami T, Yamaguchi M et al. Effects of chemical modifcation of ursodeoxycholic acid on TGR5 activation. Biol. Pharm. Bull. 34, 1-7 (2011).
109. Sepe V, Renga B, Festa C et al. Modifcation on ursodeoxycholic acid (UDCA) scaffold. Discovery of bile acid derivatives as selective agonists of cell-surface G-protein coupled bile acid receptor 1 (GP-BAR1). J. Med. Chem. 57, 7687-7701 (2014).
110. Nishimaki-Mogami T, Kawahara Y, Tamehiro N et al. 5α-Bile alcohols function as farnesoid X receptor antagonists. Biochem. Biophys. Res. Commun. 339, 386-391 (2006).
111. Iguchi Y, Kihira K, Nishimaki-Mogami T et al. Structure-activity relationship of bile alcohols as human farnesoid X receptor agonist. Steroids 75, 95-100 (2010).
112. Iguchi Y, Yamaguchi M, Sato H et al. Bile alcohols function as the ligands of membrane-type bile acid-activated G protein-coupled receptor. J. Lip. Res. 51, 1432-1441 (2010).
113. Keitel V, Görg B, Bidmon HJ et al. The bile acid receptor TGR5 (Gpbar-1) acts as a neurosteroid receptor in brain. GLIA 58, 1794-1805 (2010).
114. Abu-Hayyeh S, Papacleovoulou G, Lovgren-Sandblom A et al. Intrahepatic cholestasis of pregnancy levels of sulfated progesterone metabolites inhibit farnesoid X receptor resulting in a cholestatic phenotype. Hepatology 57, 716-726 (2012).
115. Srivastava P, Mathur N, Ghatak A. Pharmacokinetics, metabolism and excretion of hypolipidemic drug: 16-dehydropregnenolone. J. Drug Metab. Toxicol. 4, 157 (2013).
116. Kumar D, Khanna AK, Pratap R et al. Dose escalation pharmacokinetics and lipid lowering activity of a novel farnesoid X receptor modulator: 16-dehydropregnenolone. Indian J. Pharmacol. 44, 57-62 (2012).
117. Soisson SM, Parthasarathy G, Adams AD et al. Identifcation of a potent synthetic FXR agonist with an unexpected mode of binding and activation. Proc. Natl Acad. Sci. USA 105, 5337-5342 (2008).